Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. News
Jun 10, 2025 - globenewswire.com
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
May 29, 2025 - globenewswire.com
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Gyre Therapeutics, Inc. Quantitative Score
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Gyre Therapeutics, Inc. Financials
Table Compare
Compare GYRE metrics with: | |||
|---|---|---|---|
Earnings & Growth | GYRE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GYRE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GYRE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GYRE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Gyre Therapeutics, Inc. Income
Gyre Therapeutics, Inc. Balance Sheet
Gyre Therapeutics, Inc. Cash Flow
Gyre Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Gyre Therapeutics, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 2.2390 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| TBA | 0.24 | Quarterly |
| TBA | 1.43 | Quarterly |
| TBA | 0.569 | Quarterly |
Historical Market Cap
Shares Outstanding
Gyre Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Han Ying Ph.D. | Chief Executive Officer & Director |
| Mr. Weiguo Ye | Chief Operating Officer |
| Ms. Ruoyu Chen | Chief Financial Officer |
| Mr. Songjiang Ma | President & Director |
| Mr. Ping Zhang | Executive Chair |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Han Ying Ph.D. | Chief Executive Officer & Director | 1966 | 397.95K | |
| Mr. Weiguo Ye | Chief Operating Officer | Male | 1978 | 332.62K |
| Ms. Ruoyu Chen | Chief Financial Officer | Female | 1971 | 285K |
| Mr. Songjiang Ma | President & Director | Male | 1956 | -- |
| Mr. Ping Zhang | Executive Chair | Male | 1973 | -- |
Gyre Therapeutics, Inc. Insider Trades
| Date | 4 Jun |
| Name | Eastling Thomas Wilson |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 26000 |
| Date | 4 Jun |
| Name | Epstein David M. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 26000 |
| Date | 4 Jun |
| Name | Nussbaum Rodney L |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 26000 |
| Date | 4 Jun |
| Name | Parry Renate |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 26000 |
| Date | 4 Jun |
| Name | Carmichael Gordon |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 26000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 4 Jun | Eastling Thomas Wilson | Director | Acquired | A-Award | 26000 |
| 4 Jun | Epstein David M. | Director | Acquired | A-Award | 26000 |
| 4 Jun | Nussbaum Rodney L | Director | Acquired | A-Award | 26000 |
| 4 Jun | Parry Renate | Director | Acquired | A-Award | 26000 |
| 4 Jun | Carmichael Gordon | Director | Acquired | A-Award | 26000 |